Pharmacological Management of Schizophrenia

  • Philip T. Ninan


A number of different pharmacological agents have been shown to be effective in the management of schizophrenia. These pharmacological agents have been variously named antischizophrenic, antipsychotic, neuroleptic, and major tranquilizers. Though these medications do significantly ameliorate the symptoms of schizophrenia, they are not specifically anti-schizophrenic because they are effective against a number of psychotic illnesses. The term neuroleptic is a Greek derivative that literally means to take hold of the nerves. It was first used by Delay and Deniker in 1955 in reference to both chlorpromazine and reserpine (Deniker, 1983) because their extrapyramidal effects resembled central nervous system diseases. By common usage, neuroleptics came to be used interchangeably with the term antipsychotic medications. Novel antipsychotic agents exist that do not have prominent extrapyramidal side effects (e. g., clozapine). These have been called atypical neuroleptics, though a consensus is lacking on a clear definition of the term atypical.


Negative Symptom Dopamine Agonist Tardive Dyskinesia Neuroleptic Malignant Syndrome Antipsychotic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baldessarini, R. J., Cohen, B. M., & Teicher, M. M. (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry, 45, 79–91.PubMedCrossRefGoogle Scholar
  2. Baldessarini, R. J., & Davis, J. M. (1980). What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Research, 3, 115–122.PubMedCrossRefGoogle Scholar
  3. Bannon, M. J., & Roth, R. H. (1983). Pharmacology of mesocortical dopamine neurons. Pharmacological Review, 35, 53–68.Google Scholar
  4. Bunney B. S., & Aghajanian, G. (1974). In E. Usdin & S. H. Snyder (Eds.), Frontiers in catecholamine research. Oxford: Pergammon Press.Google Scholar
  5. Burke, R. E., Fahn, S., Jankovic, J., Marsden, C. D., Lang, A. E., Gollomps, S., & Ilson, J. (1982). Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology, 32, 1335–1346.PubMedCrossRefGoogle Scholar
  6. Casey, D. E. (1983). Tardive dyskinesia: What is the natural history? International Drug Therapy Newsletter, 18, 13–16.Google Scholar
  7. Davis, J. M. (1975). Overview: Maintenance therapy in psychiatry I. Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.PubMedGoogle Scholar
  8. Davis, J. M., & Garver, D. L. (1978). Neuroleptics: Clinical use in psychiatry. In L. L. Iverson, S. D. Iverson, & S. H. Snyder (Eds.), Handbook of psychopharmacology (Vol. 10, pp. 129–164). New York: Plenum Press.CrossRefGoogle Scholar
  9. Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980). Important issues in the drug treatment of schizophrenia. Schizophrenia Bulletin, 6, 70–87.PubMedCrossRefGoogle Scholar
  10. Deniker, P. (1983). Discovery of the clinical uses of neuroleptics. In M. J. Parnham & J. Bruinvels (Eds.), Discoveries in Pharmacology, Volume 1: Psycho-and Neurophar-macology (pp. 163–180). New York: Elsevier Science.Google Scholar
  11. Fuster, J. (1980). The prefrontal cortex. New York: Raven Press.Google Scholar
  12. Gardos, G. (1974). Are antipsychotic drugs interchangeable? Journal of Nervous and Mental Disease, 159, 343–348.PubMedCrossRefGoogle Scholar
  13. Gelenberg, A. J. (1987). Treating extrapyramidal reactions: Some current issues. Journal of Clinical Psychiatry, 48(9) (Suppl.), 24–27.PubMedGoogle Scholar
  14. Goldberg, S. C. (1985). Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin, 11, 453–456.PubMedCrossRefGoogle Scholar
  15. Hogan, T. P., Awad, A. G., & Eastwood, M. R. (1985). Early subjective response and prediction of outcome to neuroleptic therapy in schizophrenia. Canadian Journal of Psychiatry, 30, 246–248.Google Scholar
  16. Hogarty, G. E., & Goldberg, S. C. (1973). Drugs and sociotherapy in the aftercare of schizophrenic patients: One year-relapse rates. Archives of General Psychiatry, 28, 54–64.PubMedCrossRefGoogle Scholar
  17. Hogarty, G. E., Schooler, N. R., Ulrich, R., Mussare, F., Ferro, P., & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydro-chloride. Archives of General Psychiatry 36, 1283–1294.PubMedCrossRefGoogle Scholar
  18. Iversen, S. E., & Iversen, L. L. (1981). Behavioral pharmacology (2nd ed.). New York: Oxford University Press.Google Scholar
  19. Jeste, D. V., & Wyatt, R. J. (1982). Understanding and treating tardive dyskinesia (p. 84). New York: Guilford Press.Google Scholar
  20. Kane, J. M. (1987). Treatment of schizophrenia. Schizophrenia Bulletin, 13, 133–156.PubMedCrossRefGoogle Scholar
  21. Lydiard, B. R., & Laird, L. K. (1988). Prediction of response to antipsychotics. Journal of Clinical Psychopharmacology, 8, 3–13.PubMedGoogle Scholar
  22. National Institute of Mental Health Psychopharmacology Service, Collaborative Study Group. (1964). Phenothiazine treatment in acute schizophrenia: Effectiveness. Archives of General Psychiatry, 10, 246–261.CrossRefGoogle Scholar
  23. Neborsky, R., Janowsky, D., Munson, E., & Depry, D. (1981). Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol: Behavioral considerations. Archives of General Psychiatry, 38, 195–199.PubMedCrossRefGoogle Scholar
  24. Pope, H. G., Keck, P. E., & McElroy, S. L. (1986). Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry, 143, 1227–1232.PubMedGoogle Scholar
  25. Prien, R. F., Lewine, J., & Switalski, R. W. (1971). Discontinuation of chemotherapy for chronic schizophrenics. Hospital and Community Psychiatry, 22, 4–7.PubMedGoogle Scholar
  26. Pycock, C. J., Kerwin, R. W., & Carter, C. J. (1980). Effect of lession of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature, 286, 74–76.PubMedCrossRefGoogle Scholar
  27. Quitkin, F., Rifkin, A., & Klein, D. (1975). Very high dosage vs. standard dosage fluphenazine in schizophrenia: A double-blind study of non-chronic treatment-refractory patients. Archives of General Psychiatry, 32, 1276–1281.PubMedCrossRefGoogle Scholar
  28. Rifkin A., Quitkin, F., Kane, J. M., Struve, F., & Klein, D. F. (1978). Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry, 35, 483–489.PubMedCrossRefGoogle Scholar
  29. Rifkin A., Quitkin, F., & Klein, D. F. (1975). Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry, 32, 672–674.CrossRefGoogle Scholar
  30. Schooler, N. R., Levine, J., Severe, J. B., Brauzer, B., DiMascio A., Klerman, G. L., & Tuason, V. B. (1980). Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate. Archives of General Psychiatry, 37, 16–24.PubMedCrossRefGoogle Scholar
  31. Seidman, L. J. (1983). Schizophrenia and brain dysfunction: An integration of recent diagnostic findings. Psychology Bulletin, 94, 195.CrossRefGoogle Scholar
  32. Sramek, J. J., Simpson, G. M., Morrison, R. L., & Heiser, J. F. (1986). Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. Journal of Clinical Psychiatry, 47, 305–309.PubMedGoogle Scholar
  33. Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs. Archives of General Psychiatry, 31, 67–72.PubMedCrossRefGoogle Scholar
  34. Van Putten, T., May, P. R., & Marder, S. R. (1980). Subjective response to thiothixene and chlorpromazine. Psychopharmacology Bulletin, 16, 36–38.PubMedGoogle Scholar
  35. Van Putten, T., May, P. R. A., & Marder, S. R. (1984). Akathisia with haloperidol and thiothixene. Archives of General Psychiatry, 41, 1036–1039.PubMedCrossRefGoogle Scholar
  36. Weinberger, D. R., & Kleinman, J. E. (1986) Observations on the brain in schizophrenia. In R. E. Hales & J. A. Frances (Eds.), Psychiatry update: American Psychiatric Association annual review (Vol. 5, pp. 42–67). Washington DC: American Psychiatric Association Press.Google Scholar
  37. Widiger, T. A., Frances, A., & Trull, T. J. (1987). A psychometric analysis of the social-interpersonal and cognitive-perceptual items for the schizotypal personality disorder. Archives of General Psychiatry, 44, 741–745.PubMedCrossRefGoogle Scholar
  38. Wong, D. F., Wagner, H. N., Tune, L. E., Dannais, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, M. T., Wilson, A. A., Thomas Toung, J. K., Malat, J., Williams, J. A., O’Tuane, L. A., Snyder, S. M., Kuhar, M. J., Gjedde, A. (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 234, 1558–1563.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Philip T. Ninan
    • 1
  1. 1.Department of PsychiatryEmory University ClinicN.E., AtlantaUSA

Personalised recommendations